Norvasc to get 29% market shares of Calcium blockers in 3Q

Published: 2005-12-28 06:57:00

Updated: 2005-12-28 06:57:00

Pfizer Korea's Norvasc (amlodipine besylate), an antihypertension drug, has achieved a successful sale of this year, showing the top place at about 41% of market shares out of the total anti-hypertension drugs or 29% out of the total calcium channel blockers during the 3rd quarter this year. The ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK